Behçet's disease as a model of venous thrombosis

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 71-77

  la Regina, Micaela ^a,b   Gasparyan, Armen Yuri ^c   Orlandini, Francesco ^b   Prisco, Domenico ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ligurian East Hospital   (Italy)

^c DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Arterial thrombosis; Beh et's disease; Thrombosis; Vascular diseases; Venous thrombosis; Virchow's triad

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN; HEPARIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOMODULIN; THROMBOPLASTIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VASCULOTROPIN; VON WILLEBRAND FACTOR; WARFARIN;

ARTICLE; BEHCET DISEASE; BLOOD CLOTTING; CYTOKINE PRODUCTION; ERYTHROCYTE; FIBRINOLYSIS; FLOW KINETICS; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 78249259043     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010071     Document Type: Article

References (123)

1. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-1662.
2. Yurdakul S, Yazici H. Behçet's syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809.
3. Calamia KT, Kaklamanis PG. Behçet's disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 2008; 10: 349-355.
4. Kontogiannis V, Powell RJ. Behçet's disease. Postgrad Med J 2000; 76: 629-637.
5. Gül A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005; 4: 81-83.
6. Galeazzi M, Gasbarrini G, Ghirardello A, et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006; 24(1 Suppl 40): S79-85.
7. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease mani-festations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007; 3: 148-155.
8. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet disease. Curr Opin Rheumatol 2005; 17: 1-8.
9. Kuzu MA, Ozaslan C, Köksoy C, Gürler A, Tüzüner A. Vascular involvement in Behçet's disease: 8-year audit. World J Surg 1994; 18: 948-953.
10. Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C. Behçet's disease and cardiovascular involvement. Lupus 2005; 14: 723-6.
11. Koç Y, Güllü I, Akpek G, et al. Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-410.
12. Radke PW, Schwarz ER, Groesdonk H, Graf J, Janssens U. Thrombosis in Behcet's disease: report of a case followed by a sys-tematic review using the methodology of evidence-based medicine. J Thromb Thrombolysis 2001; 11: 137-141.
13. Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behçet's disease. Arthritis Rheum 2009; 61: 518-526.
14. Korkmaz C, Kasifoglu T, Kebapçi M. Budd-Chiari syndrome in the course of Behcet's disease: clinical and laboratory analysis of four cases. Joint Bone Spine 2007; 74: 245-8.
15. Malik GH, Sirwal IA, Pandit KA. Behcet's syndrome associated with minimal change glomerulonephritis and renal vein thrombosis. Nephron 1989; 52: 87-89.
16. Karatepe O, Ziyade S, Ugurlucan M, Gasparyan AY. eComment: treatment of pulmonary artery aneurysm in Behcet's disease-few things can make big differences. Interact Cardiovasc Thorac Surg 2009; 8: 392.
17. Marzban M, Mandegar MH, Karimi A, et al. Cardiac and great vessel involvement in Behcet's disease. J Card Surg 2008; 23: 765-768.
18. Kakafika AI, Mikhailidis DP. Smoking and aortic diseases. Circ J 2007; 71: 1173-1180.
19. Benedetti R, Brignone A, Incerti VL, Orlandini F. An atypical vascular case of Behçet's disease and consequent treatment. Intern Emerg Med 2009; 4: 179-180.
20. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascu-lar involvement in familial Mediterranean fever. Arch Med Sci 2008; 4: 465-467.
21. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008; 34: 747-761.
22. Koşar A, Haznedaroǧlu IC, Büyükaşik Y, Kirazli S, Dündar SV. Activated protein C resistance in Behçet's disease. Rheumatol Int 1998; 17: 249-250.
23. Wilson AP, Efthimiou J, Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome. Eur J Clin Invest 1988; 18: 410-414.
24. Aitchison R, Chu P, Cater DR, Harris RJ, Powell RJ. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. Ann Rheum Dis 1989; 48: 590-593.
25. Lê Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behçet's disease. A study in 25 patients. J Rheumatol 1995; 22: 2103-2113.
26. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost 1991; 66: 292-4
27. Ozoran K, Dügün N, Gürler A, Tutkak H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995; 24: 376-382.
28. Demirer S, Sengül N, Yerdel MA, et al. Haemostasis in patients with Behçet's disease. Eur J Vasc Endovasc Surg 2000; 19: 570-574.
29. Espinosa G, Font J, Tassies D, et al. Behcet's disease, encothelium and thrombosis [abstract]. Arthritis Rheumatism 2000; 43(suppl): S124.
30. Ertenli I, Kiraz S, Celik IC, et al. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behçet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Ann Rheum Dis 2001; 60: 1149-1151.
31. Akarsu M, Demirkan F, Ozsan GH, et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am J Hematol 2001; 68: 225-230.
32. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate corre-lation with anti-endothelial cell antibodies and serum myeloperoxi-dase levels. Clin Immunol 1999; 91: 330-337.
33. Lee KH, Chung HS, Bang D, Lee S. Behçet's disease sera contain-ing antiendothelial cell antibodies promote adhesion of T lympho-cytes to cultured human dermal microvascular endothelial cells. Yonsei Med J 1999; 40: 152-158
34. Tugal-Tutkun I, Urgancioglu M, Foster CS. Immunopathologic study of the conjunctiva in patients with behçet disease. Ophthalmology 1995; 102: 1660-1668.
35. Sentürk T, Aydintuǧ O, Kuzu I, et al. Adhesion molecule expression in erythema nodosum-like lesions in Behçet's disease. A histo-pathological and immunohistochemical study. Rheumatol Int 1998; 18: 51-57.
36. Haznedaroglu E, Karaaslan Y, Büyükaşik Y, et al. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis 2000; 59: 61-63
37. Kosar A, Haznedaroglu S, Karaaslan Y, et al. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int 1999; 19: 11-14
38. Ateş A, Tiryaki OA, Olmez U, Tutkak H. Serum-soluble selectin levels in patients with Behçet's disease. Clin Rheumatol 2007; 26: 411-417.
39. Sari RA, Kiziltunç A, Taysi S, Akdemir S, Gündoǧdu M. Levels of soluble E-selectin in patients with active Behcet's disease. Clin Rheumatol 2005; 24: 55-59.
40. Orem A, Vanizor B, Cimşit G, Kiran E, Deǧer O, Malkoç M. De-creased nitric oxide production in patients with Behçet's disease. Dermatology 1999; 198: 33-36.
41. Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. Rheumatology (Oxford) 2005; 44: 614-617.
42. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylargin-ine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci 2006; 36: 449-454.
43. Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Br J Dermatol 2005; 153: 526-530.
44. Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46: 50-54.
45. Akdeniz N, Esrefoglu M, Keleş MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 2004; 33: 596-599.
46. Sancak B, Onder M, Oztas MO, Bukan N, Gürer MA. Nitric oxide levels in Behçet's disease. J Eur Acad Dermatol Venereol 2003; 17: 7-9.
47. Yapişlar H, Aydogan S, Borlu M, Ascioglu O. Decreased nitric oxide and increased platelet aggregation levels in patients with Be-hçet's disease. Thromb Res 2007; 119: 461-465.
48. Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. Rheumatology (Oxford) 2005; 44: 614-617.
49. Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Behçet's disease duration, activity and severity. Eur J Intern Med 2008; 19: 541-547.
50. Kim JU, Chang HK, Lee SS, et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease and rheumatic diseases with vasculitis. Ann Rheum Dis 2003; 62: 1083-1087.
51. Ben Dhifallah I, Houman H, Khanfir M, Hamzaoui K. Endothelial nitric oxide synthase gene polymorphism is associated with Be-hçet's disease in Tunisian population. Hum Immunol 2008; 69: 661-665.
52. Nakao K, Isashiki Y, Sonoda S, Uchino E, Shimonagano Y, Saka-moto T. Nitric oxide synthase and superoxide dismutase gene po-lymorphisms in Behçet disease. Arch Ophthalmol 2007; 125: 246-251.
53. Ural AU, Yalcin A, Beyan C, Isimer A, Bayhan H. Plasma endo-thelin-1 concentrations in patients with Behçet's disease. Scand J Rheumatol 1994; 23: 322-325.
54. Ural AU. Increased plasma endothelin-1 levels in active Behçet's disease. Clin Rheumatol 1997; 16: 640.
55. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol 1998; 82: 498-503.
56. Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002; 86: 653-657.
57. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth fac-tor levels in acute coronary syndromes. Circulation 2004; 110: 2355-2360.
58. Clayton JA, Chalothorn D, Faber JE. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates col-lateral growth in ischemia. Circ Res 2008; 103: 1027-1036.
59. Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease ac-tivity in patients with Behçet's syndrome. Int J Dermatol 2003; 42: 870-875.
60. Erdem F, Gündoǧdu M, Kiki I, Ali Sari R, Kiziltunç A. Vascular endothelial and basic fibroblast growth factor serum levels in pa-tients with Behçet's disease. Rheumatol Int 2005; 25: 599-603.
61. Shaker O, Ay El-Deen MA, El Hadidi H, Grace BD, El Sherif H, Abdel Halim A. The role of heat shock protein 60, vascular endo-thelial growth factor and antiphospholipid antibodies in Behçet dis-ease. Br J Dermatol 2007; 156: 32-37.
62. Paroli MP, Teodori C, D'Alessandro M, Mariani P, Iannucci G, Paroli M. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol 2007; 17: 938-942.
63. Yalçin B, Arda N, Tezel GG, Erman M, Alli N. Expressions of vascular endothelial growth factor and CD34 in oral aphthous le-sions of Behçet's disease. Anal Quant Cytol Histol 2006; 28: 303-306.
64. Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23 (4 Suppl 38): S42-8.
65. Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Behçet's disease. J Rheumatol 2004; 31: 1785-1789.
66. Nam EJ, Han SW, Kim SU, et al. Association of vascular endothelial growth factor gene polymorphisms with Behçet disease in a Korean population. Hum Immunol 2005; 66: 1068-1073.
67. Akarsu M, Demirkan F, Ozsan GH, et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am J Hematol 2001; 68: 225-230.
68. Zöller B, García de Frutos P, Hillarp A, Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59-70.
69. Kiraz S, Ertenli I, Oztürk MA, Haznedaroǧlu IC, Celik I, Calgüneri M. Pathological haemostasis and prothrombotic state in Behçet's disease. Thromb Res 2002; 105: 125-133.
70. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis 2004; 63: 1445-1449.
71. Ateş A, Düzgün N, Ulu A, Tiryaki AO, Akar N. Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet's disease. Pathophysiol Haemost Thromb 2003; 33: 157-163.
72. Gurgey A, Balta G, Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behçet's disease. Blood Coagul Fibrinolysis 2003; 14: 121-124.
73. Espinosa G, Font J, Tàssies D, et al. Vascular involvement in Be-hçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-43.
74. Gül A, Aslantas AB, Tekinay T, Koniçe M, Ozçelik T. Procoagulant mutations and venous thrombosis in Behçet's disease. Rheu-matology (Oxford) 1999; 38: 1298-1299.
75. Toydemir PB, Elhan AH, Tükün A, et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous throm-bogenesis in Behçet's disease. J Rheumatol 2000; 27: 2849-2854.
76. Lesprit P, Wechsler B, Piette JC, et al. Activated protein C resistance caused by factor V Arg 506-->Gln mutation has no role in thrombotic manifestations of Behçet's disease. Ann Rheum Dis 1995; 54: 860.
77. Silingardi M, Salvarani C, Boiardi L, et al. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Be-hçet's disease and deep vein thrombosis. Arthritis Rheum 2004; 51: 177-183.
78. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999; 128: 352-356.
79. Ricart JM, Vayá A, Todolí J, et al. Thrombophilic risk factors and homocysteine levels in Behçet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006; 95: 618-624.
80. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
81. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-828
82. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
83. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004; 137: 850-857.
84. Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol 2004; 126: 550-556.
85. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2007; 109: 2424-2429.
86. Atalay F, Ernam D, Okten F, Akar N. Elevated FVIII and FIX level in a Behçet's disease patient with intracardiac thrombosis and pulmonary arterial aneurysms. Thromb Res 2005; 115: 159-161.
87. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1705-1715.
88. Scanu AM. Lipoprotein(a): its inheritance and molecular basis of its atherothrombotic role. Mol Cell Biochem 1992; 113: 127-131.
89. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural impli-cations for pathophysiology. Int J Clin Lab Res 1997; 27: 14-23.
90. Howard GC, Pizzo SV. Biology of disease. Lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 1994; 64: 373-385.
91. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characteri-zation of the cellular plasminogen binding site: evidence that plas-minogen 2 and lipoprotein a compete for the same site. Biochemistry 1989; 28: 2374-2377.
92. Glueck CJ, Glueck HI, Tracy T, Speirs J, McGray C, Stoop D. Relationship between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993; 42: 236-246.
93. Orem A, Deǧer O, Memiş O, Bahadir S, Ovali E, Cimşit G. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease. Ann Rheum Dis 1995; 54: 726-729.
94. Gurbuz O, Ozdemir Y, Cosar CB, Kural G. Lipoprotein (a) in Behcet's disease as an indicator of disease activity and in throm-botic complications. Eur J Ophthalmol 2001; 11: 62-65.
95. Esmat S, El Sherif H, Anwar S, Fahmy I, Elmenyawi M, Shaker O. Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications. Eur J Dermatol 2006; 16: 67-71.
96. Balik O, Gur G, Lenk N, Artuz F, Alli N. Serum lipoprotein (a) levels and Behçet's disease: is there an association? Int J Dermatol 2007; 46: 827-829.
97. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-1353.
98. Sorice M, Pittoni V, Circella A, et al. Anti-prothrombin but not pure anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb Haemost 1998; 80: 713-715.
99. de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19: 757-764.
100. Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res 2009; 123 (Suppl 3): S16-21.
101. Hull RG, Harris EN, Gharavi AE, et al. Anticardiolipin antibodies: occurrence in Behçet's syndrome. Ann Rheum Dis 1984; 43: 746-748.
102. Pereira RM, Gonçalves CR, Bueno C, Meirelles Ede S, Cossermelli W, de Oliveira RM. Anticardiolipin antibodies in Behçet's syndrome: a predictor of a more severe disease. Clin Rheumatol 1989; 8: 289-291.
103. Zouboulis CC, Büttner P, Tebbe B, Orfanos CE. Anticardiolipin antibodies in Adamantiades-Behçet's disease. Br J Dermatol 1993; 128: 281-284.
104. al-Dalaan AN, al-Ballaa SR, al-Janadi MA, Bohlega S, Bahabri S. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçets disease. Clin Rheumatol 1993; 12: 28-30.
105. Kang HJ, Lee YW, Han SH, Cho HC, Lee KM. Anticardiolipin and anti-beta2-glycoprotein I antibodies in Behcet's disease. J Korean Med Sci 1998; 13: 400-404.
106. Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford) 2001; 40: 192-195.
107. Aslan H, Pay S, Gok F, et al. Antiannexin V autoantibody in thrombophilic Behçet's disease. Rheumatol Int 2004; 24: 77-79.
108. Nalçaci M, Pekçelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behçet's disease. J Int Med Res 1998; 26: 206-208.
109. Mader R, Ziv M, Adawi M, Mader R, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. J Rheumatol 1999; 26: 2404-2408.
110. Lenk N, Ozet G, Alli N, Coban O, Erbaşi S. Protein C and protein S activities in Behçet's disease as risk factors of thrombosis. Int J Dermatol 1998; 37: 124-125.
111. Oztürk MA, Ozbalkan Z, Onat AM, et al. Decreased protein Z concentrations complicating the hypercoagulable state of Behçet's disease. Clin Appl Thromb Hemost 2003; 9: 259-263.
112. Stathakis NE, Economopoulos TC, Papayannis AG, Thomopoulos D. Platelet function, blood coagulation and fibrinolysis in Behcet's syndrome. Blut 1977; 34: 215-222
113. Ricart JM, Ramón LA, Vayá A, et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008; 141: 716-719.
114. Haim S, Brook JG, Gilhar A, et al. Platelet function in Behçet's disease. J Dermatol 1984; 11: 117-120.
115. Nakano H, Oka H, Matsuda T, et al. Spontaneous platelet aggrega-tion in patients with Behçet's disease by using laser-light scattering aggregometer. Adv Exp Med Biol 2003; 528: 437-441.
116. Akar S, Ozcan MA, Ateş H, et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost 2006; 12: 451-457.
117. Tunc SE, Aksu K, Keser G, et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet's patients. Rheumatol Int 2005; 25: 326-331.
118. Martínez M, Ricart JM, Ruiz-Aja S, et al. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events? Pathophysiol Haemost Thromb 2007; 36: 18-22.
119. Polat G, Eskandari G, Kaya TI, et al. Association of the platelet glycoprotein Ia C807T/G873A gene polymorphism and thrombosis in Behçet patients. Haematologia (Budap) 2002; 32: 121-128.
120. Demiroǧlu H, Yalçin S, Büyükaşik Y, Ozcebe OI, Dündar S. Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study. Ann Rheum Dis 1998; 57: 694-696.
121. Ricart JM, Vaya A, Todolí J, et al. Haemorheological alterations in Behçet's disease are not related to a tendency for venous thrombo-sis. Thromb Res 2005; 115: 399-404.
122. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagula-tion. Clin Rheumatol 2008; 27: 201-205.
123. Sismanoglu M, Omeroglu SN, Mansuroglu D, et al. Coronary artery disease and coronary artery bypass grafting in Behçet's disease. J Card Surg 2005; 20: 160-163.